BACKGROUND. The angiotensin-converting enzyme (ACE) D allele is more prevalent among African Americans compared with other races and ethnicities and has previously been associated with severe coronavirus disease 2019 (COVID-19) pathogenesis through excessive ACE1 activity. ACE inhibitors/angiotensin receptor blockers (ACE-I/ARB) may counteract this mechanism, but their association with COVID-19 outcomes has not been specifically tested in the African American population.

中文翻译：

---

ACE 抑制剂/血管紧张素受体阻滞剂的院内使用与非裔美国患者的 COVID-19 结果相关

背景。与其他种族和民族相比，血管紧张素转换酶 (ACE) D 等位基因在非裔美国人中更为普遍，此前曾通过过度的 ACE1 活性与严重的 2019 年冠状病毒病 (COVID-19) 发病机制相关。ACE 抑制剂/血管紧张素受体阻滞剂 (ACE-I/ARB) 可能会抵消这种机制，但它们与 COVID-19 结果的关联尚未在非裔美国人人群中进行专门测试。